Read More Analyst Ratings Downgrades News Price Target Deutsche Bank Downgrades TechTarget to Hold, Announces $45 Price Target By Benzinga Newsdesk November 10, 8:41 AM Deutsche Bank analyst Brad Zelnick downgrades TechTarget (NASDAQ:TTGT) from Buy to Hold and announces $45 price target. TTGT
Read More Analyst Ratings News Price Target RBC Capital Maintains Outperform on Visteon, Raises Price Target to $161 By Benzinga Newsdesk October 28, 10:54 AM RBC Capital analyst Joseph Spak maintains Visteon (NASDAQ:VC) with a Outperform and raises the price target from $153 to $161. VC
Read More News Tech Hey Siri, Unlock My Tesla! Latest iOS App Update Enables Seamless EV Commands By Anan Ashraf August 21, 2:18 AM Tesla drivers can now reportedly ask Siri to unlock their vehicle doors, cool their cars or even start charging. AAPL
Read More Biotech General Health Care News Medicinova Presented New Data Regarding Tumor Tissue Analysis And Clinical Outcome From A Glioblastoma Clinical Trial, MN-166-GBM-1201 Phase 1/2 Study By Benzinga Newsdesk February 21, 4:42 AM Tumor tissues were analyzed to determine potential predictors of treatment response to MN-166 (ibudilast) and temozolomide (TMZ) combination treatment. Pre-treatment tumor tissues were obtained from the resected MNOV